Trump Accelerates Psychedelic Drug Reviews, Spotlight on Ibogaine
President Trump’s order to hasten psychedelic drug reviews, especially ibogaine, signals a conservative shift toward embracing alternative therapies once deemed fringe.
On April 17, 2026, former President Donald Trump issued an executive order directing the federal government to speed up the review of certain psychedelic substances, including ibogaine. This directive aims to break bureaucratic logjams that have stalled research and approval processes on these compounds, which some conservative lawmakers and veteran groups have championed for medical use, particularly in treating addiction and PTSD.
Why This Matters: Psychedelics Enter Conservative Discourse
Ibogaine, a naturally occurring psychoactive from West Africa traditionally used in ritual contexts, has attracted growing interest for its potential to interrupt opioid addiction cycles. While research remains limited and controversial due to safety concerns—ibogaine can trigger serious cardiac side effects—advocates argue its benefits outweigh risks, especially for veterans and others battling substance dependence.
What’s remarkable is the source of momentum: a figure and political base that historically leaned toward tough-on-drugs policies. Trump’s intervention reflects a notable shift. Conservative veterans’ groups and a small but vocal faction of Republican lawmakers have pushed for recognizing psychedelics not as recreational dangers but as therapeutic tools. This mirrors a recalibration of drug policy that focuses on treatment over punishment, recognizing opioid addiction as a national crisis.
Trump’s order could accelerate FDA and DEA responsiveness on these drug classifications, potentially easing access for clinical trials or compassionate use programs. It could also recalibrate the narrative around psychedelics, further normalizing them beyond the counterculture and progressive reform circles.
Broader Context: A Wave of Psychedelic Reform
Over the past decade, psychedelics like psilocybin (magic mushrooms) and MDMA have made significant strides toward legalization and medical acceptance, buoyed by positive clinical trial results for depression and PTSD. California, Oregon, and several cities have decriminalized certain psychedelics, reflecting shifting public attitudes.
However, federal classification remains a barrier, with most psychedelics listed as Schedule I substances—deemed to have no accepted medical use and high abuse potential. Trump’s directive, while symbolic, aligns with a broader bipartisan trend toward reevaluating drug schedules and reforming substance abuse policies.
This move also touches on the urgent need for novel solutions amid America’s opioid epidemic, especially for veterans who face disproportionately high addiction and suicide rates. It signals an attempt to bridge cultural and political divides over drug policy by framing psychedelics as pragmatic public health tools.
What to Watch
The key question is how quickly federal agencies will respond and whether this will translate into concrete regulatory easing or funding boosts for research. The speed and scope of FDA and DEA policy shifts will shape whether psychedelics like ibogaine can move from experimental to mainstream treatments.
Additionally, watch how Congress reacts. While some conservative lawmakers support this shift, significant opposition remains within parts of the party and bureaucracy wary of psychedelics’ risks. Litigation and public debates over safety standards, ethics, and drug classifications loom large.
Finally, observe whether Trump seeks to re-enter national politics or influence drug policy further. His signature on this order could be a trial balloon for courting a new political constituency: veterans and conservatives advocating innovative drug therapies.
This development is a fresh chapter in America’s evolving drug policy narrative—one where psychedelics are no longer solely the province of progressives or countercultural movements but are becoming part of mainstream, even conservative, political discourse.
For deeper understanding of U.S. political dynamics and drug policy shifts, explore 
U.S. Politics and broader Global Politics.
AP News: Trump Signs Order to Speed Review of Psychedelics
